Cargando…
Defining the target: clinical aims in axial spondyloarthritis
Treat-to-target (T2T) is an emerging treatment paradigm in axial spondyloarthritis (axSpA), originally based on evidence from other inflammatory conditions, which aims to direct therapy to a clear target such as disease remission or low disease activity, with the ultimate goal of maximizing quality...
Autores principales: | Marzo-Ortega, Helena, Gaffney, Katie M, Gaffney, Karl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238221/ https://www.ncbi.nlm.nih.gov/pubmed/30445481 http://dx.doi.org/10.1093/rheumatology/key176 |
Ejemplares similares
-
Axial spondyloarthritis: coming of age
por: Marzo-Ortega, Helena
Publicado: (2020) -
Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis
por: Yahya, Fariz, et al.
Publicado: (2019) -
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
por: Zhao, Sizheng Steven, et al.
Publicado: (2023) -
Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort
por: Al Arashi, Wala, et al.
Publicado: (2018) -
The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study
por: Hamilton, Louise, et al.
Publicado: (2015)